TYRP1 and cancer: Mice that are re-challenged with chromosomally stable CD47 KO tumors (and without exogenous anti-Tyrp1 opsonization) shows increased median survival and increased immune infiltrate, further supporting the hypothesis of newly generated anti-cancer acquired immunity.